J. Cui

发表

27-Hydroxylation of 7- and 8-dehydrocholesterol in Smith–Lemli–Opitz syndrome: a novel metabolic pathway

F. Porter, C. Wassif, Jinghua Yu, 2003, Steroids.

The Amino Acid Residues Asparagine 354 and Isoleucine 372 of Human Farnesoid X Receptor Confer the Receptor with High Sensitivity to Chenodeoxycholate*

Y. Li, S. Wright, J. Schaeffer, 2002, The Journal of Biological Chemistry.

Guggulsterone Is a Farnesoid X Receptor Antagonist in Coactivator Association Assays but Acts to Enhance Transcription of Bile Salt Export Pump*

S. Wright, P. Meinke, F. Peláez, 2003, The Journal of Biological Chemistry.

Syntheses and structure-activity relationship studies of piperidine-substituted quinolones as nonpeptide gonadotropin releasing hormone antagonists.

R. DeVita, M. Wyvratt, M. Goulet, 2004, Bioorganic & medicinal chemistry letters.

Leukotriene B4 Strongly Increases Monocyte Chemoattractant Protein-1 in Human Monocytes

Jilly F. Evans, M. Struthers, F. Ujjainwalla, 2004, Arteriosclerosis, thrombosis, and vascular biology.

Lithocholic Acid Decreases Expression of Bile Salt Export Pump through Farnesoid X Receptor Antagonist Activity*

S. Wright, P. Meinke, Jinghua Yu, 2002, The Journal of Biological Chemistry.

The Farnesoid X Receptor Controls Gene Expression in a Ligand- and Promoter-selective Fashion*

N. de Pedro, S. Wright, F. Peláez, 2004, Journal of Biological Chemistry.

Farnesoid X Receptor Activates Transcription of the Phospholipid Pump MDR3*

R. Blevins, Theresa Zhang, N. de Pedro, 2003, Journal of Biological Chemistry.

Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension.

J. Metzger, M. Garcia-Calvo, D. Shevell, 2013, Bioorganic & medicinal chemistry letters.

Evaluation of endo- and exo-aryl-substitutions and central scaffold modifications on diphenyl substituted alkanes as 5-lipoxygenase activating protein inhibitors.

Jilly F. Evans, L. Chu, F. Ujjainwalla, 2012, Bioorganic & medicinal chemistry letters.

2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.

K. Lyons, M. Wyvratt, M. Goulet, 2002, Bioorganic & medicinal chemistry letters.

Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity.

K. Lyons, Y. Yang, M. Goulet, 2001, Bioorganic & medicinal chemistry letters.

A potent, nonpeptidyl 1H-quinolone antagonist for the gonadotropin-releasing hormone receptor.

R. DeVita, F. Ujjainwalla, D. Macintyre, 2001, Journal of medicinal chemistry.

Identification of Phe313 of the gonadotropin-releasing hormone (GnRH) receptor as a site critical for the binding of nonpeptide GnRH antagonists.

R. DeVita, J. Schaeffer, M. Goulet, 2000, Molecular endocrinology.

The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm

Jilly F. Evans, D. Rader, Lei Zhao, 2004, Nature Medicine.

Human Kininogen Gene Is Transactivated by the Farnesoid X Receptor*

R. Blevins, Theresa Zhang, N. de Pedro, 2003, Journal of Biological Chemistry.

Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation

J. W. Becker, S. Soisson, Alan D. Adams, 2008, Proceedings of the National Academy of Sciences.

Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947.

J. Metzger, K. Maloney, K. Rosauer, 2020, Bioorganic & medicinal chemistry letters.

Identification of neutral 4-O-alkyl quinolone nonpeptide GnRH receptor antagonists.

R. DeVita, M. Wyvratt, M. Goulet, 2004, Bioorganic & medicinal chemistry letters.

Modification of the pyridine moiety of non-peptidyl indole GnRH receptor antagonists.

M. Goulet, A. Mao, J. Cui, 2002, Bioorganic & Medicinal Chemistry Letters.

Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets.

S. Wright, Jinghua Yu, J. Cui, 2004, DNA and cell biology.